Tiziana Life Sciences Ltd

NASDAQ:TLSA

Biotechnology

Healthcare
$0.81 +2.78%

+$0.03 today

Market cap
$103.50M
Beta
0.42
P/E (TTM)
-4.0
EPS (TTM)
-$0.19
52W Low $1.04High $2.60

Volume 1.28M

Average 0.21M

TLSA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Tiziana Life Sciences LtdNASDAQ: TLSA

Cost of Revenue · Q4 FY2025 · quarter ended Dec 2025

Cost of revenue grows 139.3% year over year

Q4 FY2025 cost of revenue of $146K rose 139.3% year over year.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$146K— QoQ
Last fiscal yearDec 2025
$234K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+139.3%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
234K USD
Year-over-year change
—

Cost of Revenue vs competitors

How TLSA compares with its peers on the latest reported figures

  • TLSA's FY2025 cost of revenue of $234K is the 3rd highest of the 9 companies compared; the peer median is $73.63K.
TLSA Competitors Peer median
Cost of Revenue for TLSA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M -18.4%+80.2%30.1%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$711K +14.3%——
TLSATiziana Life Sciences LtdFY2025$234K ———
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$151K ———
IMMXImmix Biopharma, Inc.LTM Mar 2026$130.77K ———
COYACoya Therapeutics, Inc.LTM Mar 2026$16.49K -99.9%-81.6%0.2%
WHWKWhitehawk Therapeutics IncLTM Mar 2026$5K -100.0%-71.8%—
EXOZeXoZymes, Inc.LTM Mar 2026$3.64K -98.7%——
OKYOOKYO Pharma LimitedFY2025$2.56K -33.7%+1.9%—
Peer median (excluding TLSA) $73.63K-66.2%-35.0%15.1%

Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000234K
Gross Profit0000(234K)
Gross Margin—————
Research & Development17.82M15.92M10.25M5.23M10.28M
Selling, General & Admin1.15M4.76M8.26M10.28M10.77M
Operating Expenses36.93M17.93M22.73M15.79M21.05M
Depreciation & Amortization190.2K62.68K121.34K124K234K
EBITDA(35.53M)(18.85M)(21.66M)(16.62M)(21.05M)
EBITDA Margin—————
Operating Income(36.93M)(17.93M)(22.73M)(15.79M)(21.28M)
Operating Margin—————
Interest Income001.46M814K19K
Interest Expense237.41K8.6K12.64K6K18K
Other Income / Expenses967.18K(996.78K)937.89K(952K)2.85M
Income Before Tax(35.96M)(18.92M)(21.79M)(16.75M)(18.43M)
Pre-Tax Margin—————
Income Tax Expense(4.37M)0567.54K(4.88M)0
Net Income(31.59M)(18.92M)(22.36M)(11.86M)(18.43M)
Net Margin—————
EPS (Basic)(0.64)(0.36)(0.42)(0.22)(0.32)
EPS (Diluted)(0.64)(0.36)(0.42)(0.22)(0.32)
Weighted Avg Shares48.97M50.76M50.76M53.34M59.14M
Weighted Avg Shares (Diluted)48.97M50.76M50.76M53.34M59.14M

Tiziana Life Sciences Ltd

NASDAQ:TLSA

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.